Blueprint Medicines Corporation Stock News

Blueprint Medicines' (BPMC) earnings beat estimates in the fourth quarter of 2020 while revenues meet the same. Shares up.

Blueprint Medicines Corporation (BPMC) CEO Jeff Albers on Q4 2020 Results - Earnings Call Transcript

Blueprint Medicines (BPMC) delivered earnings and revenue surprises of 2.55% and -1.10%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Shares of Blueprint Medicines (NASDAQ:BPMC) were unchanged after the company reported Q4 results. Quarterly Results Earnings per share fell 13.33% over the past year to ($1.53), which beat the estimat

3 Biotech Stocks Poised to Outperform Amid Coronavirus Pandemic

CAMBRIDGE, Mass., Jan. 11, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced leadership transitions for the company's research and development organization. Effective

We highlight a few biotech companies, which outperformed the sector in 2020 and are likely to witness a winning run in the near term.

Blueprint Medicines' (BPMC) lead drug, Ayvakit, approved for PDGFRA Exon 18 mutant GIST is off to a solid start. The company's second drug, Gavreto, gets approved for two types of cancer indications.

CAMBRIDGE, Mass., Dec. 4, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherap

CAMBRIDGE, Mass., Dec. 1, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherap

Investors are hyper-focused on COVID-19 right now, but once vaccines for the virus have been approved, other healthcare stocks will start to zoom forward.

Blueprint Medicines Corporation (BPMC) CEO Jeff Albers on Q3 2020 Results - Earnings Call Transcript

Marc Schneidman's Aquilo Capital Management is a San Francisco-based, healthcare-focused long/short hedge fund that was founded in 2010. The fund uses CIO Schneidman's 20 years of industry expertise i

The upscale hotel model is upping the ante for elegance in Canada (Sponsor Content)

Halvorsen's 13F portfolio value increased from $19.21B to $23.14B. The number of positions increased from 64 to 71.